Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
Gemma L Kelly, Stephanie Grabow, Stefan P Glaser, Leah Fitzsimmons, Brandon J Aubrey, Toru Okamoto, Liz J Valente, Mikara Robati, Lin Tai, W Douglas Fairlie, Erinna F Lee, Mikael S Lindstrom, Klas G Wiman, David CS Huang, Philippe Bouillet, Martin Rowe, Alan B Rickinson, Marco J Herold, Andreas Strasser
Genes & Development | COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT | Published : 2014
Awarded by Kay Kendall Leukemia Fund Intermediate Fellowship
Awarded by National Health and Medical Research Council, Australia
Awarded by German Research Council Fellowship
Awarded by Cancer Research UK
We thank G. Siciliano and his team for help with animal husbandry, C. McLean for editorial assistance, Dr. J.M. Adams and Dr. S. Cory for advice and discussions, and Dr. Kelly Rogers for help with imaging of mice. This work is supported by a Kay Kendall Leukemia Fund Intermediate Fellowship (KKL331) and an EMBO short-term fellowship (both awarded to G.L.K.); the National Health and Medical Research Council, Australia (program grant 1016701 and fellowship 1020363 to A. S., project grant APP1049720 to M.J.H., project grant APP1041936 to W.D.F., and career development fellowship APP1024620 to E.F.L.); Cancer Research UK (program grant awarded to L.F., M. Rowe, andA.B.R.); the Leukemia Foundation; the Leukemia and Lymphoma Society (specialized center of research 7001-13); and a German Research Council Fellowship (He 5740/1-1 awarded to M.J.H.). This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government National Health and Medical Research Council Independent Research Institutes Infrastructure Support Scheme.